Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2020 Earnings Conference Call August 6, 2020 8:00 AM ET Company Participants Juli Miller - Senior Director, IR Adrian Rawcliffe - CEO Elliot Norry - Senior VP and Chief Medical Officer Helen Tayton-Martin - Co-Founder and Chief Business Officer John Lunger - Chief Patient Supply Officer Conference Call Participants Marc Frahm - Cowen and Company Tony Butler - ROTH Capital Mohit Bansal - Citigroup Kelsey Goodwin - Guggenheim Securities Nick Abbott - Wells Fargo S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2020 Earnings Conference Call May 14, 2020 8:00 AM ET Company Participants Juli Miller - Director of IR Adrian Rawcliffe - CEO Helen Tayton-Martin - Chief Business Officer Elliot Norry - Chief Medical Officer Conference Call Participants Marc Frahm - Cowen and Company Tony Butler - Roth Capital Mohit Bansal - Citigroup Nick Abbott - Wells Fargo Mara Goldstein - Mizuho Operator Ladies and gentlemen, thank you for standing by. And welcome to the Adaptimmune Q1 202 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicabl ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2019 Earnings Conference Call February 27, 2020 8:00 AM ET Company Participants Juli Miller - Director of Investor Relations Adrian Rawcliffe - Chief Executive Officer Helen Tayton-Martin - Chief Business Officer Elliot Norry - Chief Medical Officer Conference Call Participants Tony Butler - Roth Capital Marc Frahm - Cowen and Company Kelsey Goodwin - Guggenheim Securities James Shannon - Citi Jonathan Chang - SVB Leerink Operator Ladies and gentlemen, thank you ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (St ...

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Q3 2019 Earnings Conference Call November 6, 2019 8:00 AM ET Company Participants Juli Miller - Director, IR Adrian Rawcliffe - CEO, Principal Accounting Officer & Director Elliot Norry - Acting Chief Medical Officer John Lunger - Chief Patient Supply Officer Michael Garone - Interim CFO Conference Call Participants Mohit Bansal - Citigroup Marc Frahm - Cowen and Company Tony Butler - Roth Capital Partners Nicholas Abbott - Wells Fargo Securities Michael Schmidt - ...